Gland Pharma profit and loss

Latest FY26

Revenue: ₹6,431cr+14.5% on FY25
EBITDA: ₹1,630cr+28.4% on FY25
Net profit: ₹1,027cr+47.1% on FY25
EPS: ₹62.35+47.1% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	6,725	6,431	5,617	5,665	3,625	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	320	316	214	170	240
	7,045	6,747	5,830	5,835	3,865
	2,271	2,240	1,972	2,022	1,717
	7.7	6.6	14.5	23.1	15.6
	67.9	−3.4	103	128	−46.9
	1,665	1,629	1,402	1,257	403
	26.1	33.3	42.0	26.2	7.4
	434	424	378	345	147
	963	929	856	902	511
	5,434	5,258	4,767	4,702	2,754
	1,751	1,630	1,269	1,333	1,025
	1,317	1,206	891	989	878
Profit
	1,611	1,489	1,063	1,133	1,111
	−24.3	−24.3	0.0	0.0	−56.5
	1,587	1,465	1,063	1,133	1,055
	482	459	372	346	276
	−24.3	−21.6	−7.8	14.3	−2.8
	458	437	364	360	274
	1,129	1,027	699	772	781
	1,129	1,027	699	772	781
	218	431	55.4	−7.9	−1.4
	1,347	1,458	754	765	780
	1,129	1,027	699	772	781
Per share
	₹68.51	₹62.35	₹42.40	₹46.90	₹47.44
	₹68.47	₹62.28	₹42.40	₹46.89	₹47.43
Other comprehensive income — detail
	218	431	55.4	—	—
	17.4	13.6	−1.6	−2.5	−3.0
	4.3	3.4	−0.4	—	—
	—	—	—	−0.6	−0.8
	205	421	—	—	0.8
	0.0	0.0	−56.6	—	—
	—	—	—	6.0	0.0
	1,347	1,458	754	765	780
Per share — as-filed variants
	₹68.51	₹62.35	₹42.40	₹46.90	₹47.44
	₹68.47	₹62.28	₹42.40	₹46.89	₹47.43
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	4,379	4,188	3,526	3,492	1,939
	65.1%	65.1%	62.8%	61.6%	53.5%
Adjusted (ex-exceptional items) — derived
	1,611	1,489	1,063	1,133	1,111
	−24.3	−24.3	0.0	0.0	−56.5
	1,146	1,044	699	772	823
	₹69.56	₹63.39	₹42.40	₹46.90	₹49.98

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

GLAND₹3,074.50

Gland Pharma Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersDIVISLAB AUROPHARMA PPLPHARMA SYNGENE WOCKPHARMA ASTERDM COHANCE LALPATHLABMcap ₹50,655 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Revenue from Operations	3,624.6	5,664.7	5,616.5	6,430.7	6,725.3
Other Income	240.5	170.2	213.6	316.3	320.0
Total Income	3,865.1	5,835.0	5,830.1	6,747.0	7,045.3
Expenses
+ Cost of Materials Consumed	1,716.8	2,022.1	1,972.5	2,239.7	2,270.6
+ Purchases of Stock-in-Trade	15.6	23.1	14.5	6.6	7.7
+ Changes in Inventories	-46.9	127.9	103.4	-3.4	67.9
+ Employee Benefit Expense	403.3	1,256.9	1,401.6	1,628.8	1,664.8
+ Finance Costs	7.4	26.2	42.0	33.3	26.1
+ Depreciation & Amortisation	146.7	344.6	377.9	423.7	433.9
+ Other Expenses	511.2	901.7	855.6	929.3	963.2
Total Expenses	2,754.0	4,702.4	4,767.5	5,258.1	5,434.2
EBITDA	1,024.8	1,333.1	1,268.9	1,629.5	1,751.1
EBIT	878.0	988.5	891.1	1,205.9	1,317.3
Profit
PBT before Exceptional Items	1,111.0	1,132.5	1,062.7	1,488.9	1,611.2
+ Exceptional Items	-56.5	0.0	0.0	-24.3	-24.3
Pretax Income	1,054.6	1,132.5	1,062.7	1,464.6	1,586.8
+ Current Tax	276.3	345.7	372.0	458.9	482.4
+ Deferred Tax	-2.8	14.3	-7.8	-21.6	-24.3
Tax Expense	273.5	360.1	364.1	437.3	458.0
Net Income	781.0	772.5	698.5	1,027.3	1,128.8
+ Net Income — Continuing Ops	781.0	772.5	698.5	1,027.3	1,128.8
+ Other Comprehensive Income	-1.4	-7.9	55.4	431.0	217.8
Total Comprehensive Income	779.6	764.6	753.9	1,458.3	1,346.6
Net Income to Common	781.0	772.5	698.5	1,027.3	1,128.8
Per Share
Basic EPS	47.44	46.90	42.40	62.35	68.51
Diluted EPS	47.43	46.89	42.40	62.28	68.47
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	55.4	431.0	217.8
+ Items NOT to be Reclassified to P&L	-3.0	-2.5	-1.6	13.6	17.4
+ Tax on Items NOT to be Reclassified	—	—	-0.4	3.4	4.3
+ Tax on Items NOT to be Reclassified — alt tag	-0.8	-0.6	—	—	—
+ Items to be Reclassified to P&L	0.8	—	—	420.9	204.7
+ Tax on Items to be Reclassified	—	—	-56.6	0.0	0.0
+ Tax on Items to be Reclassified — alt tag	0.0	6.0	—	—	—
Comprehensive Income — Owners of Parent	779.6	764.6	753.9	1,458.3	1,346.6
Per Share — as-filed variants
Basic EPS — Continuing Operations	47.44	46.90	42.40	62.35	68.51
Diluted EPS — Continuing Operations	47.43	46.89	42.40	62.28	68.47
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	1,939.2	3,491.6	3,526.1	4,187.7	4,379.2
Gross Margin %	53.50	61.64	62.78	65.12	65.11
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	1,111.0	1,132.5	1,062.7	1,488.9	1,611.2
− Exceptional Items (reconciliation)	-56.5	0.0	0.0	-24.3	-24.3
Net Income Adj (tax-effected)	822.9	772.5	698.5	1,044.4	1,146.1
EPS Adj	49.98	46.90	42.40	63.39	69.56
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	1.00	1.00	1.00	1.00	1.00
Paid Up Equity Capital	16.5	16.5	16.5	16.5	16.5

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.